Daveym Smith News Today

Among the ways to enhance bedside and webside manners of medical students and medical doctors comes along newcomer generative AI. Heres what this is all about.

An international team including researchers from The University of Texas Health Science Center at San Antonio have developed a novel set of metrics called "immune resilience" (IR) and shown that individuals with optimal levels of IR are more likely to live longer, resist HIV and influenza infections, and survive COVID-19 infections, among outcomes studied.

Multinational study identifies immune resilience as a factor that influences life span, HIV/AIDS, flu, sepsis mortality, recurrent skin cancer, and COVID-19 mortality. Researchers from The University of Texas Health Science Center at San Antonio, working with collaborators in five countries, toda

Researchers at University of California San Diego School of Medicine, with colleagues from the ACTIV-2 trial, part of the U.S. government's response to COVID-19, investigated whether symptoms of COVID-19 recurred following a two-day symptom-free period in persons who did not receive any treatment for the disease.

Our zestly daily links: eerie Halloween, jay self control, AI helping you cheat? moar nasty variants, moar Covid damage, horse fire aid? China chip war, Russia grain row, Israel elections, FB + Twitter spying, small business distress

A CDC study of the COVID-19 treatment drug, Paxlovid shows that instances of symptom rebound after treatment may be due to under exposure to the drug

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was completed, prompting the Centers for Disease Control and Prevention (CDC) to iss

 E-Mail IMAGE: Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. view more  Credit: NIAID LA JOLLA--A new study led by scientists at La Jolla Institute for Immunology (LJI) suggests that T cells try to fight SARS-CoV-2 by targeting a broad range of sites on the virus--beyond the key sites on the viruss spike protein. By attacking the virus...

Credit: Jenna Hambrick, La Jolla Institute for Immunology LA JOLLA--New data suggest that nearly all COVID-19 survivors have the immune cells necessary to fight re-infection. The findings, based on analyses of blood samples from 188 COVID-19 patients, suggest that responses to the novel coronavirus, SARS-CoV-2, from all major players in the "adaptive" immune system, which learns to fight specific pathogens, can last for at least eight months after the onset of symptoms from the initial infectio...